nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—migraine—Prednisone—hematologic cancer	0.535	1	CpDpCtD
Methylergometrine—CYP3A4—Bexarotene—hematologic cancer	0.0198	0.0829	CbGbCtD
Methylergometrine—CYP3A4—Lomustine—hematologic cancer	0.0184	0.0771	CbGbCtD
Methylergometrine—CYP3A4—Busulfan—hematologic cancer	0.0184	0.0771	CbGbCtD
Methylergometrine—CYP3A4—Thiotepa—hematologic cancer	0.0164	0.0687	CbGbCtD
Methylergometrine—CYP3A4—Methoxsalen—hematologic cancer	0.0128	0.0534	CbGbCtD
Methylergometrine—CYP3A4—Bortezomib—hematologic cancer	0.0122	0.0508	CbGbCtD
Methylergometrine—CYP3A4—Daunorubicin—hematologic cancer	0.0116	0.0486	CbGbCtD
Methylergometrine—CYP3A4—Cytarabine—hematologic cancer	0.0103	0.0429	CbGbCtD
Methylergometrine—CYP3A4—Teniposide—hematologic cancer	0.0101	0.0422	CbGbCtD
Methylergometrine—CYP3A4—Ifosfamide—hematologic cancer	0.00933	0.039	CbGbCtD
Methylergometrine—CYP3A4—Imatinib—hematologic cancer	0.00891	0.0372	CbGbCtD
Methylergometrine—CYP3A4—Ruxolitinib—hematologic cancer	0.00839	0.035	CbGbCtD
Methylergometrine—CYP3A4—Nilotinib—hematologic cancer	0.0081	0.0338	CbGbCtD
Methylergometrine—CYP3A4—Vinorelbine—hematologic cancer	0.00803	0.0335	CbGbCtD
Methylergometrine—CYP3A4—Triamcinolone—hematologic cancer	0.00734	0.0307	CbGbCtD
Methylergometrine—CYP3A4—Dasatinib—hematologic cancer	0.00716	0.0299	CbGbCtD
Methylergometrine—CYP3A4—Mitoxantrone—hematologic cancer	0.00707	0.0295	CbGbCtD
Methylergometrine—CYP3A4—Betamethasone—hematologic cancer	0.0063	0.0263	CbGbCtD
Methylergometrine—CYP3A4—Prednisolone—hematologic cancer	0.00622	0.026	CbGbCtD
Methylergometrine—CYP3A4—Prednisone—hematologic cancer	0.00587	0.0245	CbGbCtD
Methylergometrine—CYP3A4—Irinotecan—hematologic cancer	0.00557	0.0232	CbGbCtD
Methylergometrine—CYP3A4—Vinblastine—hematologic cancer	0.00495	0.0207	CbGbCtD
Methylergometrine—CYP3A4—Vincristine—hematologic cancer	0.00487	0.0203	CbGbCtD
Methylergometrine—CYP3A4—Etoposide—hematologic cancer	0.00446	0.0186	CbGbCtD
Methylergometrine—CYP3A4—Dexamethasone—hematologic cancer	0.00367	0.0153	CbGbCtD
Methylergometrine—CYP3A4—Doxorubicin—hematologic cancer	0.00304	0.0127	CbGbCtD
Methylergometrine—Diarrhoea—Vinorelbine—hematologic cancer	0.000117	0.000689	CcSEcCtD
Methylergometrine—Nausea—Melphalan—hematologic cancer	0.000117	0.000684	CcSEcCtD
Methylergometrine—Dizziness—Bortezomib—hematologic cancer	0.000116	0.000682	CcSEcCtD
Methylergometrine—Anaphylactic shock—Prednisolone—hematologic cancer	0.000116	0.000681	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Mitoxantrone—hematologic cancer	0.000116	0.000679	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Irinotecan—hematologic cancer	0.000116	0.000679	CcSEcCtD
Methylergometrine—Paraesthesia—Cisplatin—hematologic cancer	0.000115	0.000677	CcSEcCtD
Methylergometrine—Tachycardia—Etoposide—hematologic cancer	0.000115	0.000674	CcSEcCtD
Methylergometrine—Abdominal pain—Vincristine—hematologic cancer	0.000115	0.000674	CcSEcCtD
Methylergometrine—Dyspnoea—Cisplatin—hematologic cancer	0.000115	0.000672	CcSEcCtD
Methylergometrine—Hyperhidrosis—Etoposide—hematologic cancer	0.000114	0.000668	CcSEcCtD
Methylergometrine—Dizziness—Vinorelbine—hematologic cancer	0.000113	0.000666	CcSEcCtD
Methylergometrine—Nausea—Lenalidomide—hematologic cancer	0.000113	0.000666	CcSEcCtD
Methylergometrine—Convulsion—Triamcinolone—hematologic cancer	0.000113	0.000665	CcSEcCtD
Methylergometrine—Tachycardia—Prednisolone—hematologic cancer	0.000113	0.000665	CcSEcCtD
Methylergometrine—Angina pectoris—Epirubicin—hematologic cancer	0.000113	0.000663	CcSEcCtD
Methylergometrine—Hypertension—Triamcinolone—hematologic cancer	0.000113	0.000663	CcSEcCtD
Methylergometrine—Hyperhidrosis—Prednisolone—hematologic cancer	0.000112	0.000659	CcSEcCtD
Methylergometrine—Diarrhoea—Thiotepa—hematologic cancer	0.000112	0.000658	CcSEcCtD
Methylergometrine—Abdominal pain—Mitoxantrone—hematologic cancer	0.000112	0.000656	CcSEcCtD
Methylergometrine—Abdominal pain—Irinotecan—hematologic cancer	0.000112	0.000656	CcSEcCtD
Methylergometrine—Nausea—Hydroxyurea—hematologic cancer	0.000112	0.000656	CcSEcCtD
Methylergometrine—Vomiting—Bortezomib—hematologic cancer	0.000112	0.000656	CcSEcCtD
Methylergometrine—Vomiting—Bleomycin—hematologic cancer	0.000111	0.000651	CcSEcCtD
Methylergometrine—Rash—Bortezomib—hematologic cancer	0.000111	0.00065	CcSEcCtD
Methylergometrine—Dermatitis—Bortezomib—hematologic cancer	0.000111	0.000649	CcSEcCtD
Methylergometrine—Headache—Bortezomib—hematologic cancer	0.00011	0.000646	CcSEcCtD
Methylergometrine—Hypotension—Etoposide—hematologic cancer	0.00011	0.000645	CcSEcCtD
Methylergometrine—Rash—Bleomycin—hematologic cancer	0.00011	0.000645	CcSEcCtD
Methylergometrine—Dermatitis—Bleomycin—hematologic cancer	0.00011	0.000645	CcSEcCtD
Methylergometrine—Vomiting—Vinorelbine—hematologic cancer	0.000109	0.00064	CcSEcCtD
Methylergometrine—Diarrhoea—Thalidomide—hematologic cancer	0.000108	0.000636	CcSEcCtD
Methylergometrine—Dizziness—Thiotepa—hematologic cancer	0.000108	0.000636	CcSEcCtD
Methylergometrine—Rash—Vinorelbine—hematologic cancer	0.000108	0.000635	CcSEcCtD
Methylergometrine—Dermatitis—Vinorelbine—hematologic cancer	0.000108	0.000634	CcSEcCtD
Methylergometrine—Headache—Vinorelbine—hematologic cancer	0.000107	0.000631	CcSEcCtD
Methylergometrine—Anaphylactic shock—Triamcinolone—hematologic cancer	0.000107	0.000626	CcSEcCtD
Methylergometrine—Paraesthesia—Etoposide—hematologic cancer	0.000106	0.00062	CcSEcCtD
Methylergometrine—Haematuria—Methotrexate—hematologic cancer	0.000105	0.000618	CcSEcCtD
Methylergometrine—Dyspnoea—Etoposide—hematologic cancer	0.000105	0.000616	CcSEcCtD
Methylergometrine—Dizziness—Thalidomide—hematologic cancer	0.000105	0.000615	CcSEcCtD
Methylergometrine—Angina pectoris—Doxorubicin—hematologic cancer	0.000105	0.000614	CcSEcCtD
Methylergometrine—Nausea—Bortezomib—hematologic cancer	0.000104	0.000612	CcSEcCtD
Methylergometrine—Paraesthesia—Prednisolone—hematologic cancer	0.000104	0.000612	CcSEcCtD
Methylergometrine—Tachycardia—Triamcinolone—hematologic cancer	0.000104	0.000611	CcSEcCtD
Methylergometrine—Vomiting—Thiotepa—hematologic cancer	0.000104	0.000611	CcSEcCtD
Methylergometrine—Diarrhoea—Carmustine—hematologic cancer	0.000104	0.000611	CcSEcCtD
Methylergometrine—Nausea—Bleomycin—hematologic cancer	0.000104	0.000608	CcSEcCtD
Methylergometrine—Rash—Thiotepa—hematologic cancer	0.000103	0.000606	CcSEcCtD
Methylergometrine—Dermatitis—Thiotepa—hematologic cancer	0.000103	0.000606	CcSEcCtD
Methylergometrine—Hyperhidrosis—Triamcinolone—hematologic cancer	0.000103	0.000606	CcSEcCtD
Methylergometrine—Diarrhoea—Alitretinoin—hematologic cancer	0.000103	0.000605	CcSEcCtD
Methylergometrine—Convulsion—Dexamethasone—hematologic cancer	0.000103	0.000603	CcSEcCtD
Methylergometrine—Convulsion—Betamethasone—hematologic cancer	0.000103	0.000603	CcSEcCtD
Methylergometrine—Headache—Thiotepa—hematologic cancer	0.000103	0.000602	CcSEcCtD
Methylergometrine—Hypertension—Betamethasone—hematologic cancer	0.000102	0.000601	CcSEcCtD
Methylergometrine—Hypertension—Dexamethasone—hematologic cancer	0.000102	0.000601	CcSEcCtD
Methylergometrine—Diarrhoea—Ifosfamide—hematologic cancer	0.000102	0.000598	CcSEcCtD
Methylergometrine—Nausea—Vinorelbine—hematologic cancer	0.000102	0.000598	CcSEcCtD
Methylergometrine—Vomiting—Thalidomide—hematologic cancer	0.000101	0.000591	CcSEcCtD
Methylergometrine—Dizziness—Carmustine—hematologic cancer	0.000101	0.000591	CcSEcCtD
Methylergometrine—Rash—Thalidomide—hematologic cancer	9.99e-05	0.000586	CcSEcCtD
Methylergometrine—Dermatitis—Thalidomide—hematologic cancer	9.98e-05	0.000586	CcSEcCtD
Methylergometrine—Dizziness—Alitretinoin—hematologic cancer	9.97e-05	0.000585	CcSEcCtD
Methylergometrine—Diarrhoea—Vincristine—hematologic cancer	9.94e-05	0.000583	CcSEcCtD
Methylergometrine—Headache—Thalidomide—hematologic cancer	9.92e-05	0.000583	CcSEcCtD
Methylergometrine—Haematuria—Epirubicin—hematologic cancer	9.86e-05	0.000579	CcSEcCtD
Methylergometrine—Dizziness—Ifosfamide—hematologic cancer	9.85e-05	0.000578	CcSEcCtD
Methylergometrine—Nausea—Thiotepa—hematologic cancer	9.73e-05	0.000571	CcSEcCtD
Methylergometrine—Anaphylactic shock—Betamethasone—hematologic cancer	9.68e-05	0.000568	CcSEcCtD
Methylergometrine—Anaphylactic shock—Dexamethasone—hematologic cancer	9.68e-05	0.000568	CcSEcCtD
Methylergometrine—Diarrhoea—Irinotecan—hematologic cancer	9.68e-05	0.000568	CcSEcCtD
Methylergometrine—Diarrhoea—Mitoxantrone—hematologic cancer	9.68e-05	0.000568	CcSEcCtD
Methylergometrine—Vomiting—Carmustine—hematologic cancer	9.67e-05	0.000568	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Etoposide—hematologic cancer	9.62e-05	0.000565	CcSEcCtD
Methylergometrine—Dizziness—Vincristine—hematologic cancer	9.6e-05	0.000564	CcSEcCtD
Methylergometrine—Rash—Carmustine—hematologic cancer	9.59e-05	0.000563	CcSEcCtD
Methylergometrine—Dermatitis—Carmustine—hematologic cancer	9.58e-05	0.000563	CcSEcCtD
Methylergometrine—Vomiting—Alitretinoin—hematologic cancer	9.58e-05	0.000563	CcSEcCtD
Methylergometrine—Paraesthesia—Triamcinolone—hematologic cancer	9.58e-05	0.000562	CcSEcCtD
Methylergometrine—Headache—Carmustine—hematologic cancer	9.53e-05	0.000559	CcSEcCtD
Methylergometrine—Dyspnoea—Triamcinolone—hematologic cancer	9.51e-05	0.000558	CcSEcCtD
Methylergometrine—Rash—Alitretinoin—hematologic cancer	9.5e-05	0.000558	CcSEcCtD
Methylergometrine—Nervous system disorder—Betamethasone—hematologic cancer	9.5e-05	0.000557	CcSEcCtD
Methylergometrine—Nervous system disorder—Dexamethasone—hematologic cancer	9.5e-05	0.000557	CcSEcCtD
Methylergometrine—Dermatitis—Alitretinoin—hematologic cancer	9.5e-05	0.000557	CcSEcCtD
Methylergometrine—Vomiting—Ifosfamide—hematologic cancer	9.47e-05	0.000556	CcSEcCtD
Methylergometrine—Tachycardia—Betamethasone—hematologic cancer	9.45e-05	0.000555	CcSEcCtD
Methylergometrine—Tachycardia—Dexamethasone—hematologic cancer	9.45e-05	0.000555	CcSEcCtD
Methylergometrine—Bradycardia—Epirubicin—hematologic cancer	9.45e-05	0.000555	CcSEcCtD
Methylergometrine—Headache—Alitretinoin—hematologic cancer	9.44e-05	0.000554	CcSEcCtD
Methylergometrine—Diarrhoea—Gemcitabine—hematologic cancer	9.43e-05	0.000553	CcSEcCtD
Methylergometrine—Nausea—Thalidomide—hematologic cancer	9.41e-05	0.000552	CcSEcCtD
Methylergometrine—Rash—Ifosfamide—hematologic cancer	9.39e-05	0.000551	CcSEcCtD
Methylergometrine—Dermatitis—Ifosfamide—hematologic cancer	9.38e-05	0.000551	CcSEcCtD
Methylergometrine—Hyperhidrosis—Dexamethasone—hematologic cancer	9.36e-05	0.000549	CcSEcCtD
Methylergometrine—Hyperhidrosis—Betamethasone—hematologic cancer	9.36e-05	0.000549	CcSEcCtD
Methylergometrine—Dizziness—Irinotecan—hematologic cancer	9.35e-05	0.000549	CcSEcCtD
Methylergometrine—Abdominal pain—Etoposide—hematologic cancer	9.3e-05	0.000546	CcSEcCtD
Methylergometrine—Tinnitus—Methotrexate—hematologic cancer	9.25e-05	0.000543	CcSEcCtD
Methylergometrine—Vomiting—Vincristine—hematologic cancer	9.24e-05	0.000542	CcSEcCtD
Methylergometrine—Cardiac disorder—Methotrexate—hematologic cancer	9.21e-05	0.00054	CcSEcCtD
Methylergometrine—Rash—Vincristine—hematologic cancer	9.16e-05	0.000538	CcSEcCtD
Methylergometrine—Dermatitis—Vincristine—hematologic cancer	9.15e-05	0.000537	CcSEcCtD
Methylergometrine—Haematuria—Doxorubicin—hematologic cancer	9.12e-05	0.000536	CcSEcCtD
Methylergometrine—Headache—Vincristine—hematologic cancer	9.1e-05	0.000534	CcSEcCtD
Methylergometrine—Hypotension—Dexamethasone—hematologic cancer	9.05e-05	0.000531	CcSEcCtD
Methylergometrine—Hypotension—Betamethasone—hematologic cancer	9.05e-05	0.000531	CcSEcCtD
Methylergometrine—Nausea—Carmustine—hematologic cancer	9.04e-05	0.00053	CcSEcCtD
Methylergometrine—Vomiting—Irinotecan—hematologic cancer	8.99e-05	0.000528	CcSEcCtD
Methylergometrine—Vomiting—Mitoxantrone—hematologic cancer	8.99e-05	0.000528	CcSEcCtD
Methylergometrine—Nausea—Alitretinoin—hematologic cancer	8.95e-05	0.000526	CcSEcCtD
Methylergometrine—Convulsion—Prednisone—hematologic cancer	8.95e-05	0.000525	CcSEcCtD
Methylergometrine—Hypertension—Prednisone—hematologic cancer	8.92e-05	0.000524	CcSEcCtD
Methylergometrine—Rash—Mitoxantrone—hematologic cancer	8.92e-05	0.000524	CcSEcCtD
Methylergometrine—Rash—Irinotecan—hematologic cancer	8.92e-05	0.000524	CcSEcCtD
Methylergometrine—Dermatitis—Irinotecan—hematologic cancer	8.91e-05	0.000523	CcSEcCtD
Methylergometrine—Dermatitis—Mitoxantrone—hematologic cancer	8.91e-05	0.000523	CcSEcCtD
Methylergometrine—Headache—Mitoxantrone—hematologic cancer	8.86e-05	0.00052	CcSEcCtD
Methylergometrine—Headache—Irinotecan—hematologic cancer	8.86e-05	0.00052	CcSEcCtD
Methylergometrine—Nausea—Ifosfamide—hematologic cancer	8.85e-05	0.000519	CcSEcCtD
Methylergometrine—Diarrhoea—Cisplatin—hematologic cancer	8.79e-05	0.000516	CcSEcCtD
Methylergometrine—Vomiting—Gemcitabine—hematologic cancer	8.76e-05	0.000514	CcSEcCtD
Methylergometrine—Bradycardia—Doxorubicin—hematologic cancer	8.74e-05	0.000513	CcSEcCtD
Methylergometrine—Paraesthesia—Dexamethasone—hematologic cancer	8.7e-05	0.00051	CcSEcCtD
Methylergometrine—Paraesthesia—Betamethasone—hematologic cancer	8.7e-05	0.00051	CcSEcCtD
Methylergometrine—Rash—Gemcitabine—hematologic cancer	8.69e-05	0.00051	CcSEcCtD
Methylergometrine—Dermatitis—Gemcitabine—hematologic cancer	8.68e-05	0.000509	CcSEcCtD
Methylergometrine—Tinnitus—Epirubicin—hematologic cancer	8.66e-05	0.000508	CcSEcCtD
Methylergometrine—Headache—Gemcitabine—hematologic cancer	8.63e-05	0.000507	CcSEcCtD
Methylergometrine—Nausea—Vincristine—hematologic cancer	8.63e-05	0.000506	CcSEcCtD
Methylergometrine—Cardiac disorder—Epirubicin—hematologic cancer	8.62e-05	0.000506	CcSEcCtD
Methylergometrine—Anaphylactic shock—Prednisone—hematologic cancer	8.43e-05	0.000495	CcSEcCtD
Methylergometrine—Nausea—Mitoxantrone—hematologic cancer	8.4e-05	0.000493	CcSEcCtD
Methylergometrine—Nausea—Irinotecan—hematologic cancer	8.4e-05	0.000493	CcSEcCtD
Methylergometrine—Nervous system disorder—Prednisone—hematologic cancer	8.27e-05	0.000485	CcSEcCtD
Methylergometrine—Tachycardia—Prednisone—hematologic cancer	8.23e-05	0.000483	CcSEcCtD
Methylergometrine—Nausea—Gemcitabine—hematologic cancer	8.18e-05	0.00048	CcSEcCtD
Methylergometrine—Vomiting—Cisplatin—hematologic cancer	8.17e-05	0.000479	CcSEcCtD
Methylergometrine—Hyperhidrosis—Prednisone—hematologic cancer	8.15e-05	0.000479	CcSEcCtD
Methylergometrine—Rash—Cisplatin—hematologic cancer	8.1e-05	0.000475	CcSEcCtD
Methylergometrine—Dermatitis—Cisplatin—hematologic cancer	8.09e-05	0.000475	CcSEcCtD
Methylergometrine—Diarrhoea—Etoposide—hematologic cancer	8.05e-05	0.000473	CcSEcCtD
Methylergometrine—Tinnitus—Doxorubicin—hematologic cancer	8.01e-05	0.00047	CcSEcCtD
Methylergometrine—Cardiac disorder—Doxorubicin—hematologic cancer	7.97e-05	0.000468	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.92e-05	0.000465	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Betamethasone—hematologic cancer	7.92e-05	0.000465	CcSEcCtD
Methylergometrine—Dizziness—Etoposide—hematologic cancer	7.78e-05	0.000457	CcSEcCtD
Methylergometrine—Muscle spasms—Epirubicin—hematologic cancer	7.77e-05	0.000456	CcSEcCtD
Methylergometrine—Dizziness—Prednisolone—hematologic cancer	7.67e-05	0.00045	CcSEcCtD
Methylergometrine—Abdominal pain—Dexamethasone—hematologic cancer	7.65e-05	0.000449	CcSEcCtD
Methylergometrine—Abdominal pain—Betamethasone—hematologic cancer	7.65e-05	0.000449	CcSEcCtD
Methylergometrine—Nausea—Cisplatin—hematologic cancer	7.63e-05	0.000448	CcSEcCtD
Methylergometrine—Paraesthesia—Prednisone—hematologic cancer	7.57e-05	0.000444	CcSEcCtD
Methylergometrine—Convulsion—Methotrexate—hematologic cancer	7.48e-05	0.000439	CcSEcCtD
Methylergometrine—Vomiting—Etoposide—hematologic cancer	7.48e-05	0.000439	CcSEcCtD
Methylergometrine—Rash—Etoposide—hematologic cancer	7.42e-05	0.000435	CcSEcCtD
Methylergometrine—Dermatitis—Etoposide—hematologic cancer	7.41e-05	0.000435	CcSEcCtD
Methylergometrine—Headache—Etoposide—hematologic cancer	7.37e-05	0.000433	CcSEcCtD
Methylergometrine—Chest pain—Methotrexate—hematologic cancer	7.35e-05	0.000432	CcSEcCtD
Methylergometrine—Rash—Prednisolone—hematologic cancer	7.32e-05	0.000429	CcSEcCtD
Methylergometrine—Dermatitis—Prednisolone—hematologic cancer	7.31e-05	0.000429	CcSEcCtD
Methylergometrine—Headache—Prednisolone—hematologic cancer	7.27e-05	0.000427	CcSEcCtD
Methylergometrine—Muscle spasms—Doxorubicin—hematologic cancer	7.19e-05	0.000422	CcSEcCtD
Methylergometrine—Palpitations—Epirubicin—hematologic cancer	7.14e-05	0.000419	CcSEcCtD
Methylergometrine—Dizziness—Triamcinolone—hematologic cancer	7.06e-05	0.000414	CcSEcCtD
Methylergometrine—Anaphylactic shock—Methotrexate—hematologic cancer	7.05e-05	0.000414	CcSEcCtD
Methylergometrine—Convulsion—Epirubicin—hematologic cancer	7e-05	0.000411	CcSEcCtD
Methylergometrine—Nausea—Etoposide—hematologic cancer	6.99e-05	0.00041	CcSEcCtD
Methylergometrine—Hypertension—Epirubicin—hematologic cancer	6.98e-05	0.00041	CcSEcCtD
Methylergometrine—Nervous system disorder—Methotrexate—hematologic cancer	6.91e-05	0.000406	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Prednisone—hematologic cancer	6.9e-05	0.000405	CcSEcCtD
Methylergometrine—Nausea—Prednisolone—hematologic cancer	6.89e-05	0.000405	CcSEcCtD
Methylergometrine—Chest pain—Epirubicin—hematologic cancer	6.88e-05	0.000404	CcSEcCtD
Methylergometrine—Hyperhidrosis—Methotrexate—hematologic cancer	6.81e-05	0.0004	CcSEcCtD
Methylergometrine—Vomiting—Triamcinolone—hematologic cancer	6.79e-05	0.000398	CcSEcCtD
Methylergometrine—Rash—Triamcinolone—hematologic cancer	6.73e-05	0.000395	CcSEcCtD
Methylergometrine—Dermatitis—Triamcinolone—hematologic cancer	6.72e-05	0.000395	CcSEcCtD
Methylergometrine—Headache—Triamcinolone—hematologic cancer	6.69e-05	0.000392	CcSEcCtD
Methylergometrine—Abdominal pain—Prednisone—hematologic cancer	6.67e-05	0.000391	CcSEcCtD
Methylergometrine—Diarrhoea—Betamethasone—hematologic cancer	6.63e-05	0.000389	CcSEcCtD
Methylergometrine—Diarrhoea—Dexamethasone—hematologic cancer	6.63e-05	0.000389	CcSEcCtD
Methylergometrine—Palpitations—Doxorubicin—hematologic cancer	6.61e-05	0.000388	CcSEcCtD
Methylergometrine—Anaphylactic shock—Epirubicin—hematologic cancer	6.6e-05	0.000387	CcSEcCtD
Methylergometrine—Hypotension—Methotrexate—hematologic cancer	6.59e-05	0.000387	CcSEcCtD
Methylergometrine—Convulsion—Doxorubicin—hematologic cancer	6.48e-05	0.00038	CcSEcCtD
Methylergometrine—Nervous system disorder—Epirubicin—hematologic cancer	6.47e-05	0.00038	CcSEcCtD
Methylergometrine—Hypertension—Doxorubicin—hematologic cancer	6.46e-05	0.000379	CcSEcCtD
Methylergometrine—Tachycardia—Epirubicin—hematologic cancer	6.44e-05	0.000378	CcSEcCtD
Methylergometrine—Dizziness—Betamethasone—hematologic cancer	6.4e-05	0.000376	CcSEcCtD
Methylergometrine—Dizziness—Dexamethasone—hematologic cancer	6.4e-05	0.000376	CcSEcCtD
Methylergometrine—Hyperhidrosis—Epirubicin—hematologic cancer	6.38e-05	0.000374	CcSEcCtD
Methylergometrine—Chest pain—Doxorubicin—hematologic cancer	6.37e-05	0.000374	CcSEcCtD
Methylergometrine—Nausea—Triamcinolone—hematologic cancer	6.34e-05	0.000372	CcSEcCtD
Methylergometrine—Paraesthesia—Methotrexate—hematologic cancer	6.33e-05	0.000371	CcSEcCtD
Methylergometrine—Dyspnoea—Methotrexate—hematologic cancer	6.28e-05	0.000369	CcSEcCtD
Methylergometrine—Hypotension—Epirubicin—hematologic cancer	6.16e-05	0.000362	CcSEcCtD
Methylergometrine—Vomiting—Dexamethasone—hematologic cancer	6.16e-05	0.000361	CcSEcCtD
Methylergometrine—Vomiting—Betamethasone—hematologic cancer	6.16e-05	0.000361	CcSEcCtD
Methylergometrine—Rash—Dexamethasone—hematologic cancer	6.11e-05	0.000358	CcSEcCtD
Methylergometrine—Rash—Betamethasone—hematologic cancer	6.11e-05	0.000358	CcSEcCtD
Methylergometrine—Anaphylactic shock—Doxorubicin—hematologic cancer	6.1e-05	0.000358	CcSEcCtD
Methylergometrine—Dermatitis—Dexamethasone—hematologic cancer	6.1e-05	0.000358	CcSEcCtD
Methylergometrine—Dermatitis—Betamethasone—hematologic cancer	6.1e-05	0.000358	CcSEcCtD
Methylergometrine—Headache—Betamethasone—hematologic cancer	6.07e-05	0.000356	CcSEcCtD
Methylergometrine—Headache—Dexamethasone—hematologic cancer	6.07e-05	0.000356	CcSEcCtD
Methylergometrine—Nervous system disorder—Doxorubicin—hematologic cancer	5.98e-05	0.000351	CcSEcCtD
Methylergometrine—Tachycardia—Doxorubicin—hematologic cancer	5.96e-05	0.00035	CcSEcCtD
Methylergometrine—Paraesthesia—Epirubicin—hematologic cancer	5.92e-05	0.000348	CcSEcCtD
Methylergometrine—Hyperhidrosis—Doxorubicin—hematologic cancer	5.9e-05	0.000346	CcSEcCtD
Methylergometrine—Dyspnoea—Epirubicin—hematologic cancer	5.88e-05	0.000345	CcSEcCtD
Methylergometrine—Diarrhoea—Prednisone—hematologic cancer	5.77e-05	0.000339	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Methotrexate—hematologic cancer	5.76e-05	0.000338	CcSEcCtD
Methylergometrine—Nausea—Betamethasone—hematologic cancer	5.75e-05	0.000338	CcSEcCtD
Methylergometrine—Nausea—Dexamethasone—hematologic cancer	5.75e-05	0.000338	CcSEcCtD
Methylergometrine—Hypotension—Doxorubicin—hematologic cancer	5.7e-05	0.000335	CcSEcCtD
Methylergometrine—Dizziness—Prednisone—hematologic cancer	5.58e-05	0.000327	CcSEcCtD
Methylergometrine—Abdominal pain—Methotrexate—hematologic cancer	5.57e-05	0.000327	CcSEcCtD
Methylergometrine—Paraesthesia—Doxorubicin—hematologic cancer	5.48e-05	0.000322	CcSEcCtD
Methylergometrine—Dyspnoea—Doxorubicin—hematologic cancer	5.44e-05	0.000319	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Epirubicin—hematologic cancer	5.39e-05	0.000317	CcSEcCtD
Methylergometrine—Vomiting—Prednisone—hematologic cancer	5.36e-05	0.000315	CcSEcCtD
Methylergometrine—Rash—Prednisone—hematologic cancer	5.32e-05	0.000312	CcSEcCtD
Methylergometrine—Dermatitis—Prednisone—hematologic cancer	5.31e-05	0.000312	CcSEcCtD
Methylergometrine—Headache—Prednisone—hematologic cancer	5.28e-05	0.00031	CcSEcCtD
Methylergometrine—Abdominal pain—Epirubicin—hematologic cancer	5.21e-05	0.000306	CcSEcCtD
Methylergometrine—Nausea—Prednisone—hematologic cancer	5.01e-05	0.000294	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.99e-05	0.000293	CcSEcCtD
Methylergometrine—Abdominal pain—Doxorubicin—hematologic cancer	4.82e-05	0.000283	CcSEcCtD
Methylergometrine—Diarrhoea—Methotrexate—hematologic cancer	4.82e-05	0.000283	CcSEcCtD
Methylergometrine—Dizziness—Methotrexate—hematologic cancer	4.66e-05	0.000274	CcSEcCtD
Methylergometrine—Diarrhoea—Epirubicin—hematologic cancer	4.51e-05	0.000265	CcSEcCtD
Methylergometrine—Vomiting—Methotrexate—hematologic cancer	4.48e-05	0.000263	CcSEcCtD
Methylergometrine—Rash—Methotrexate—hematologic cancer	4.44e-05	0.000261	CcSEcCtD
Methylergometrine—Dermatitis—Methotrexate—hematologic cancer	4.44e-05	0.000261	CcSEcCtD
Methylergometrine—Headache—Methotrexate—hematologic cancer	4.42e-05	0.000259	CcSEcCtD
Methylergometrine—Dizziness—Epirubicin—hematologic cancer	4.36e-05	0.000256	CcSEcCtD
Methylergometrine—Vomiting—Epirubicin—hematologic cancer	4.19e-05	0.000246	CcSEcCtD
Methylergometrine—Nausea—Methotrexate—hematologic cancer	4.19e-05	0.000246	CcSEcCtD
Methylergometrine—Diarrhoea—Doxorubicin—hematologic cancer	4.18e-05	0.000245	CcSEcCtD
Methylergometrine—Rash—Epirubicin—hematologic cancer	4.16e-05	0.000244	CcSEcCtD
Methylergometrine—Dermatitis—Epirubicin—hematologic cancer	4.15e-05	0.000244	CcSEcCtD
Methylergometrine—Headache—Epirubicin—hematologic cancer	4.13e-05	0.000243	CcSEcCtD
Methylergometrine—Dizziness—Doxorubicin—hematologic cancer	4.04e-05	0.000237	CcSEcCtD
Methylergometrine—Nausea—Epirubicin—hematologic cancer	3.92e-05	0.00023	CcSEcCtD
Methylergometrine—Vomiting—Doxorubicin—hematologic cancer	3.88e-05	0.000228	CcSEcCtD
Methylergometrine—Rash—Doxorubicin—hematologic cancer	3.85e-05	0.000226	CcSEcCtD
Methylergometrine—Dermatitis—Doxorubicin—hematologic cancer	3.84e-05	0.000226	CcSEcCtD
Methylergometrine—Headache—Doxorubicin—hematologic cancer	3.82e-05	0.000224	CcSEcCtD
Methylergometrine—Nausea—Doxorubicin—hematologic cancer	3.62e-05	0.000213	CcSEcCtD
Methylergometrine—HTR1E—Signaling Pathways—MAPK3—hematologic cancer	5.62e-06	0.000103	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PDGFRA—hematologic cancer	5.59e-06	0.000102	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—MAPK3—hematologic cancer	5.59e-06	0.000102	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—JAK1—hematologic cancer	5.57e-06	0.000102	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PRKCG—hematologic cancer	5.57e-06	0.000102	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CREB1—hematologic cancer	5.56e-06	0.000101	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—IDH1—hematologic cancer	5.54e-06	0.000101	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—BRAF—hematologic cancer	5.49e-06	0.0001	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCC3—hematologic cancer	5.48e-06	0.0001	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTO1—hematologic cancer	5.48e-06	0.0001	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—TXN—hematologic cancer	5.48e-06	0.0001	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MAP2K1—hematologic cancer	5.48e-06	0.0001	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MYC—hematologic cancer	5.46e-06	9.98e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TGFB1—hematologic cancer	5.45e-06	9.95e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CD—hematologic cancer	5.44e-06	9.94e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—FGFR3—hematologic cancer	5.44e-06	9.94e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCL2—hematologic cancer	5.44e-06	9.93e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL6R—hematologic cancer	5.42e-06	9.9e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CREBBP—hematologic cancer	5.41e-06	9.89e-05	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—PIK3CA—hematologic cancer	5.39e-06	9.85e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAPK14—hematologic cancer	5.38e-06	9.84e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SPHK1—hematologic cancer	5.36e-06	9.8e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—KRAS—hematologic cancer	5.35e-06	9.77e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—KRAS—hematologic cancer	5.33e-06	9.73e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ESR1—hematologic cancer	5.28e-06	9.65e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—FN1—hematologic cancer	5.22e-06	9.53e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—FGF2—hematologic cancer	5.21e-06	9.52e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL2RA—hematologic cancer	5.2e-06	9.51e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL2—hematologic cancer	5.17e-06	9.44e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MAP2K1—hematologic cancer	5.16e-06	9.44e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—BAD—hematologic cancer	5.16e-06	9.42e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NFKBIA—hematologic cancer	5.16e-06	9.42e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—UGT1A1—hematologic cancer	5.15e-06	9.41e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TERT—hematologic cancer	5.15e-06	9.4e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3R1—hematologic cancer	5.14e-06	9.39e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CD—hematologic cancer	5.13e-06	9.37e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NOTCH1—hematologic cancer	5.11e-06	9.33e-05	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—PIK3CA—hematologic cancer	5.08e-06	9.28e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—KRAS—hematologic cancer	5.05e-06	9.22e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—KRAS—hematologic cancer	5.02e-06	9.18e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PDGFB—hematologic cancer	5.02e-06	9.18e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.01e-06	9.16e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.01e-06	9.16e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CD80—hematologic cancer	5e-06	9.14e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—JAK2—hematologic cancer	4.99e-06	9.12e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CG—hematologic cancer	4.99e-06	9.12e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KIT—hematologic cancer	4.99e-06	9.12e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—NRAS—hematologic cancer	4.99e-06	9.12e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PIK3CA—hematologic cancer	4.91e-06	8.98e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—FGF2—hematologic cancer	4.91e-06	8.98e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TSC2—hematologic cancer	4.91e-06	8.97e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTPN11—hematologic cancer	4.91e-06	8.96e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PIK3CA—hematologic cancer	4.89e-06	8.94e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALOX5—hematologic cancer	4.88e-06	8.92e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MDM2—hematologic cancer	4.87e-06	8.9e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3R1—hematologic cancer	4.84e-06	8.85e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—MAPK3—hematologic cancer	4.78e-06	8.74e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TP53—hematologic cancer	4.75e-06	8.69e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CREB1—hematologic cancer	4.75e-06	8.68e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MTOR—hematologic cancer	4.74e-06	8.66e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CB—hematologic cancer	4.74e-06	8.66e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NUP98—hematologic cancer	4.73e-06	8.64e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—FGFR3—hematologic cancer	4.72e-06	8.63e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—JAK2—hematologic cancer	4.71e-06	8.6e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—BRAF—hematologic cancer	4.69e-06	8.57e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAPK14—hematologic cancer	4.68e-06	8.54e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCL2—hematologic cancer	4.65e-06	8.5e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PIK3CA—hematologic cancer	4.64e-06	8.47e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL6R—hematologic cancer	4.64e-06	8.47e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CREBBP—hematologic cancer	4.63e-06	8.46e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PIK3CA—hematologic cancer	4.62e-06	8.43e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MDM2—hematologic cancer	4.6e-06	8.4e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ADCY7—hematologic cancer	4.59e-06	8.39e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NCOA3—hematologic cancer	4.59e-06	8.39e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ESR1—hematologic cancer	4.59e-06	8.38e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NUP214—hematologic cancer	4.56e-06	8.33e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—HRAS—hematologic cancer	4.55e-06	8.31e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—FN1—hematologic cancer	4.53e-06	8.28e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—HRAS—hematologic cancer	4.53e-06	8.27e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TP53—hematologic cancer	4.49e-06	8.19e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NFKBIA—hematologic cancer	4.48e-06	8.18e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—BAD—hematologic cancer	4.48e-06	8.18e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CB—hematologic cancer	4.47e-06	8.17e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MTOR—hematologic cancer	4.47e-06	8.17e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—MTR—hematologic cancer	4.47e-06	8.16e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.47e-06	8.16e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CDKN1B—hematologic cancer	4.45e-06	8.13e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NOTCH1—hematologic cancer	4.43e-06	8.1e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAP2K1—hematologic cancer	4.42e-06	8.07e-05	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—AKT1—hematologic cancer	4.4e-06	8.04e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CD—hematologic cancer	4.39e-06	8.02e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ENO2—hematologic cancer	4.38e-06	8e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CASP3—hematologic cancer	4.36e-06	7.97e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL2—hematologic cancer	4.36e-06	7.96e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IL6—hematologic cancer	4.35e-06	7.95e-05	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—PIK3CA—hematologic cancer	4.35e-06	7.94e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CD80—hematologic cancer	4.34e-06	7.94e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CG—hematologic cancer	4.34e-06	7.92e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KIT—hematologic cancer	4.34e-06	7.92e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—NRAS—hematologic cancer	4.34e-06	7.92e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—IL6—hematologic cancer	4.33e-06	7.92e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—KRAS—hematologic cancer	4.3e-06	7.85e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—HRAS—hematologic cancer	4.29e-06	7.84e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—HRAS—hematologic cancer	4.27e-06	7.8e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTPN11—hematologic cancer	4.26e-06	7.78e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.25e-06	7.76e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCND1—hematologic cancer	4.25e-06	7.76e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—JUN—hematologic cancer	4.24e-06	7.74e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—FGF2—hematologic cancer	4.2e-06	7.68e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CDKN1B—hematologic cancer	4.2e-06	7.67e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SDC1—hematologic cancer	4.15e-06	7.59e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—MAPK3—hematologic cancer	4.15e-06	7.59e-05	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—AKT1—hematologic cancer	4.15e-06	7.58e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3R1—hematologic cancer	4.14e-06	7.57e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CREB1—hematologic cancer	4.13e-06	7.54e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CASP3—hematologic cancer	4.11e-06	7.51e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL2—hematologic cancer	4.11e-06	7.5e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CDKN1A—hematologic cancer	4.11e-06	7.5e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IL6—hematologic cancer	4.11e-06	7.5e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PTEN—hematologic cancer	4.1e-06	7.49e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—IL6—hematologic cancer	4.09e-06	7.47e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—BRAF—hematologic cancer	4.08e-06	7.45e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCL2—hematologic cancer	4.04e-06	7.38e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—JAK2—hematologic cancer	4.03e-06	7.36e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL6R—hematologic cancer	4.03e-06	7.36e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	4.02e-06	7.34e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—AKT1—hematologic cancer	4.02e-06	7.34e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MAPK8—hematologic cancer	4.01e-06	7.32e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCND1—hematologic cancer	4e-06	7.31e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—AKT1—hematologic cancer	4e-06	7.3e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—JUN—hematologic cancer	4e-06	7.3e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3CA—hematologic cancer	3.95e-06	7.21e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MDM2—hematologic cancer	3.93e-06	7.18e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EP300—hematologic cancer	3.91e-06	7.14e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CDKN1A—hematologic cancer	3.87e-06	7.08e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PTEN—hematologic cancer	3.86e-06	7.06e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	3.84e-06	7.01e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MTOR—hematologic cancer	3.83e-06	6.99e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CB—hematologic cancer	3.83e-06	6.99e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	3.81e-06	6.96e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SRC—hematologic cancer	3.8e-06	6.94e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—AKT1—hematologic cancer	3.79e-06	6.92e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MAPK8—hematologic cancer	3.78e-06	6.91e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	3.78e-06	6.9e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—AKT1—hematologic cancer	3.77e-06	6.89e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	3.73e-06	6.82e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VEGFA—hematologic cancer	3.7e-06	6.76e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EP300—hematologic cancer	3.69e-06	6.73e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—STAT3—hematologic cancer	3.66e-06	6.7e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NRAS—hematologic cancer	3.66e-06	6.68e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—HRAS—hematologic cancer	3.65e-06	6.67e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—FGF2—hematologic cancer	3.65e-06	6.67e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	3.6e-06	6.58e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CDKN1B—hematologic cancer	3.59e-06	6.56e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SRC—hematologic cancer	3.58e-06	6.55e-05	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—AKT1—hematologic cancer	3.55e-06	6.49e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CD44—hematologic cancer	3.53e-06	6.45e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NQO1—hematologic cancer	3.53e-06	6.45e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CASP3—hematologic cancer	3.52e-06	6.43e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL2—hematologic cancer	3.51e-06	6.42e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MAPK3—hematologic cancer	3.5e-06	6.4e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—JAK2—hematologic cancer	3.5e-06	6.39e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—IL6—hematologic cancer	3.5e-06	6.39e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VEGFA—hematologic cancer	3.49e-06	6.38e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—STAT3—hematologic cancer	3.46e-06	6.31e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NRAS—hematologic cancer	3.45e-06	6.3e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	3.43e-06	6.26e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCND1—hematologic cancer	3.43e-06	6.26e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—JUN—hematologic cancer	3.42e-06	6.24e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MDM2—hematologic cancer	3.41e-06	6.24e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MYC—hematologic cancer	3.41e-06	6.22e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TGFB1—hematologic cancer	3.4e-06	6.21e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYCS—hematologic cancer	3.34e-06	6.1e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	3.32e-06	6.07e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MTOR—hematologic cancer	3.32e-06	6.07e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.32e-06	6.07e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	3.31e-06	6.05e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTEN—hematologic cancer	3.31e-06	6.04e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MAPK3—hematologic cancer	3.3e-06	6.03e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	3.23e-06	5.91e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	3.23e-06	5.89e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MYC—hematologic cancer	3.21e-06	5.87e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TGFB1—hematologic cancer	3.2e-06	5.85e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	3.17e-06	5.8e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EP300—hematologic cancer	3.15e-06	5.76e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—KRAS—hematologic cancer	3.15e-06	5.75e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	3.12e-06	5.7e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	3.08e-06	5.63e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SRC—hematologic cancer	3.07e-06	5.6e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CASP3—hematologic cancer	3.06e-06	5.58e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL2—hematologic cancer	3.05e-06	5.57e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL6—hematologic cancer	3.04e-06	5.55e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	2.99e-06	5.46e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	2.97e-06	5.43e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—JUN—hematologic cancer	2.97e-06	5.42e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—KRAS—hematologic cancer	2.97e-06	5.42e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—STAT3—hematologic cancer	2.96e-06	5.4e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NRAS—hematologic cancer	2.95e-06	5.39e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.95e-06	5.38e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	2.89e-06	5.28e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	2.88e-06	5.26e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	2.87e-06	5.24e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	2.82e-06	5.16e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	2.81e-06	5.13e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	2.8e-06	5.12e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TP53—hematologic cancer	2.8e-06	5.11e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.79e-06	5.09e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MYC—hematologic cancer	2.75e-06	5.02e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	2.74e-06	5.01e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EP300—hematologic cancer	2.74e-06	5e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	2.73e-06	4.98e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.71e-06	4.94e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.71e-06	4.94e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HRAS—hematologic cancer	2.67e-06	4.89e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SRC—hematologic cancer	2.66e-06	4.86e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TP53—hematologic cancer	2.64e-06	4.82e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	2.59e-06	4.74e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	2.57e-06	4.69e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	2.56e-06	4.68e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL6—hematologic cancer	2.56e-06	4.68e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	2.54e-06	4.64e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HRAS—hematologic cancer	2.52e-06	4.61e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	2.45e-06	4.48e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL6—hematologic cancer	2.41e-06	4.41e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.39e-06	4.37e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MYC—hematologic cancer	2.39e-06	4.36e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	2.38e-06	4.35e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AKT1—hematologic cancer	2.36e-06	4.31e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.33e-06	4.26e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.26e-06	4.12e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AKT1—hematologic cancer	2.23e-06	4.07e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	2.2e-06	4.03e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	2.16e-06	3.94e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL6—hematologic cancer	2.07e-06	3.77e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	2.03e-06	3.7e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.01e-06	3.67e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.96e-06	3.58e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.91e-06	3.48e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.87e-06	3.42e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.86e-06	3.4e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.79e-06	3.28e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.77e-06	3.23e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALB—hematologic cancer	1.74e-06	3.19e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.67e-06	3.05e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.65e-06	3.02e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.54e-06	2.81e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTEN—hematologic cancer	1.33e-06	2.43e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—EP300—hematologic cancer	1.27e-06	2.32e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	9.39e-07	1.72e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKT1—hematologic cancer	7.67e-07	1.4e-05	CbGpPWpGaD
